The critical platforms of PROTAC validation

Evaluation of the efficacy of ADC in vitro and in vivo

Evaluating cancer therapies combining radiotherapy with immunotherapy or inhibitors of the DNA damage response

Establishment of spatial transcriptomics assay to find the mechanism of immune therapy against tumors

Mouse hind limb tumor metastatic model to evaluate prophylaxis and treatment

Development of an integrated in vitro and in vivo OVA-specific system for cancer vaccine discovery

Developing a panel of orthotopic syngeneic tumor models for IO drug discovery

Developing drug-induced resistant tumor models for efficacy evaluation of next-generation anticancer therapies

Intra-carotid artery brain metastasis models for the evaluation of lung and breast cancer drugs

Brain metastasis mouse models for the evaluation of multikinase inhibitors on ROS1-fusion-positive lung cancer

Comprehensive Comparison of Three-dimensional (3D) culture systems as Compound Screening Platforms in Primary Cancer Cell Lines

MEETING NEURODEGENERATIVE DISEASE HEAD-ON WITH EMERGING DRUG DISCOVERY STRATEGIES

DNA-encoded chemical libraries

Optimizing Drug Pipelines With Biophysical Methods

Tumor evolution selectively inactivates the core microRNA machinery for immune evasion

RARE DISEASES: OPPORTUNITIES AND CHALLENGES FOR TREATMENTS DELIVERED BY ADENO-ASSOCIATED VIRUSES

HIJACKING CELLULAR MECHANISMS TO TREAT COMPLEX DISEASES

Identification of tofacitinib, Filgotinib and Ruxolitinib on experimental Sjögren's syndrome model in mice

Establishment and Optimization of scRNA-seq assay to find the mechanism of immune therapy against tumors

Tumor evolution inactivates microRNA machinery for immune evasion

Establishment of In vitro Human T cell Exhaustion Model to Enable High Throughput

Myeloid-dominated spontaneous tumor models as the tool for the evaluation of immune modulators

Construction of Siglec-15 knockout mouse model and validating the effect of Siglec-15 KO on T cell response

Establishment of KRAS-G12C inhibitor induced resistant tumor models enable the development of new generation KRAS-G12C inhibitors and combinatorial strategies

Establishment of KRAS G12C mutant patient-derived xenograft (PDX) models for pre-clinical evaluation of KRAS G12C targeted anticancer therapy

Validation of GVHD in mouse model for preclinical efficacy screen

Engineered cell line panel complemented with in vivo models to enable next-generation target therapy discovery in cancer

Establishment of drug induced resistant tumor models enable the development of next generation anticancer therapeutics

Outsourcing Drug Discovery And Development

Considerations for emerging biophama companies

How Diversity In Therapeutic Strategies Is Expanding The Drug Discovery Toolbox

Bifunctional Molecules: A Diverse New Modality That Unlocks New Target Classes

Inflammasome Activation in M2 Macrophage Restrain the Immune Supperssive Function

Validation of the Combinatorial Effect of Blinatumomab and Nivolumab in Caner Therapy

Enabling Technology for Targeted Protein Degradation

Unlocking the potential of DEL | Inspire Hit Discovery

Interview of Dr. Xuanjia Peng

Faster with high-speed fragment screening —Accelerate your drug discovery campaign

Magical Power of QM

To Empower Organic Syntheses

Drug Hunter: Discovering New Frontiers in Cancer Treatments & Beyond

Interview of Dr. Phil Jones, VP of Therapeutics Discovery